Literature DB >> 18201785

Future costs in cost effectiveness analysis.

Robert H Lee1.   

Abstract

This paper resolves several controversies in CEA. Generalizing [Garber, A.M., Phelps, C.E., 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16 (1), 1-31], the paper shows accounting for unrelated future costs distorts decision making. After replicating [Meltzer, D., 1997. Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics 16 (1), 33-64] quite different conclusion that unrelated future costs should be included in CEA, the paper shows that Meltzer's findings result from modeling the budget constraint as an annuity, which is problematic. The paper also shows that related costs should be included in CEA. This holds for a variety of models, including a health maximization model. CEA should treat costs in the manner recommended by Garber and Phelps.

Entities:  

Mesh:

Year:  2007        PMID: 18201785     DOI: 10.1016/j.jhealeco.2007.09.011

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  9 in total

1.  Standardizing the inclusion of indirect medical costs in economic evaluations.

Authors:  Pieter H M van Baal; Albert Wong; Laurentius C J Slobbe; Johan J Polder; Werner B F Brouwer; G Ardine de Wit
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

Review 2.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

4.  Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors:  Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

5.  Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Authors:  Daniel T Grima; Lisa M Bernard; Elizabeth S Dunn; Philip A McFarlane; David C Mendelssohn
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

6.  Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

Authors:  Blanca Gros; Antonio Galán; Emilio González-Parra; Jose A Herrero; Maria Echave; Stefan Vegter; Keith Tolley; Itziar Oyagüez
Journal:  Health Econ Rev       Date:  2015-06-11

7.  Pertussis post-exposure prophylaxis among household contacts: a cost-utility analysis.

Authors:  Nisha Thampi; Ipek Gurol-Urganci; Natasha S Crowcroft; Beate Sander
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

8.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.

Authors:  Linda M de Vries; Pieter H M van Baal; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

9.  Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary.

Authors:  Erik Nord; Christoffer Lamøy
Journal:  Pharmacoecon Open       Date:  2018-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.